Investigational drug · Phase 2
LSALT Peptide
Also called: Metablok
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Kidney Injury, Cardiac Surgery.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "LSALT Peptide"
First trial start
2024
Mar 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LSALT Peptide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Kidney Injury
- Cardiac Surgery
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "LSALT Peptide" as an intervention, largest first.
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
- LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac SurgeryPivotal-lookingRecruiting
Arch Biopartners Inc.Industry
NCT05879432 · 240 participants (planned) · Start Mar 8, 2024 · Primary completion Mar 2027
Drug: LSALT Peptide; Placebo · For: Acute Kidney Injury; Cardiac Surgery
Sites: Calgary, Canada; New Westminster, Canada; Toronto, Canada · 9 sites in all
Arch Biopartners Inc.Industry
NCT04402957 · 61 participants · Start Oct 14, 2020 · Primary completion May 27, 2021
Drug: LSALT peptide; Placebo · For: COVID; Severe Acute Respiratory Syndrome; Sars-CoV2 and 2 more
Sites: San Diego, California; Fort Lauderdale, Florida; Shreveport, Louisiana · 7 sites in all
Arch Biopartners Inc.Industry
NCT03772678 · 52 participants · Start Jun 27, 2019 · Primary completion Mar 31, 2020
Drug: LSALT peptide · For: None - Study is to Determine Safety in Healthy Participants
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19).
Somayaji R, Luke DR, Lau A, et al. · BMJ Open 2024
- Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury.
Lau A, Rahn JJ, Chappellaz M, et al. · Sci Adv 2022
Also in development for Acute Kidney Injury
- QRX-3EseronatePhase 32 trials
Ebima Clifford Okundaye · Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- R2R01Phase 22 trials
River 2 Renal Corp. · Acute Kidney Injury, Hepatorenal Syndrome
- AZD4144Phase 21 trial
AstraZeneca · Sepsis, Acute Kidney Injury
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.